These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12676261)

  • 1. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.
    Nicolatou-Galitis O; Sotiropoulou-Lontou A; Velegraki A; Pissakas G; Kolitsi G; Kyprianou K; Kouloulias V; Papanikolaou I; Yiotakis I; Dardoufas K
    Oral Oncol; 2003 Jun; 39(4):397-401. PubMed ID: 12676261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
    J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
    Vacha P; Marx M; Engel A; Richter E; Feyerabend T
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current status of prevention and management of radiation-induced xerostomia].
    Ma DY; Qiu WL; Zhang CP
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
    [No Abstract]   [Full Text] [Related]  

  • 7. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
    Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
    Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
    Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
    Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
    Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
    Büntzel J; Küttner K; Fröhlich D; Glatzel M
    Ann Oncol; 1998 May; 9(5):505-9. PubMed ID: 9653491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
    Batcha M
    Oncol Nurs Forum; 2000 May; 27(4):615-6. PubMed ID: 10833684
    [No Abstract]   [Full Text] [Related]  

  • 19. In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. (Int j radiat oncol biol phys 2007;67:651-659).
    Messerschmidt GL; Oleka N
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651-2; author reply 1652. PubMed ID: 18035221
    [No Abstract]   [Full Text] [Related]  

  • 20. Amifostine: a radioprotector in locally advanced head and neck tumors.
    Wagner W; Prott FJ; Schonekas KG
    Oncol Rep; 1998; 5(5):1255-7. PubMed ID: 9683846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.